780 related articles for article (PubMed ID: 32646783)
21. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
22. Functional Parameters of
Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of baseline
Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
[TBL] [Abstract][Full Text] [Related]
26. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.
Mikhaeel NG; Smith D; Dunn JT; Phillips M; Møller H; Fields PA; Wrench D; Barrington SF
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1209-19. PubMed ID: 26902371
[TBL] [Abstract][Full Text] [Related]
27. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
28. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
[TBL] [Abstract][Full Text] [Related]
29. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
30. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of metabolic tumour volume and total lesion glycolysis in
Jiménez-Ballvé A; García García-Esquinas M; Salsidua-Arroyo O; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Fuentes Ferrer ME; Rodríguez Rey C; Román-Santamaría JM; Moreno F; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2016; 35(6):365-372. PubMed ID: 26948652
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
33. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients.
Czibor S; Carr R; Redondo F; Auewarakul CU; Cerci JJ; Paez D; Fanti S; Györke T
Nucl Med Commun; 2023 Apr; 44(4):291-301. PubMed ID: 36705233
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity.
Ryu IS; Kim JS; Roh JL; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):452-61. PubMed ID: 24081448
[TBL] [Abstract][Full Text] [Related]
35. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
37. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
[TBL] [Abstract][Full Text] [Related]
38. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
39. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]